刘俊江1 张蕴霞2 李瑾宜1 李连印1 李守宾1 高双友1.p16、survivin、cyclin D1 在膀胱尿路上皮癌中的表达及意义[J].现代生物医学进展英文版,2012,12(7):1309-1311. |
p16、survivin、cyclin D1 在膀胱尿路上皮癌中的表达及意义 |
The Expression of p16, CyclinD1 and Survivin in Transitional CellCarcinoma of Bladder(TCC) and their Implications |
|
DOI: |
中文关键词: P16 Cyclin D1 Survivin |
英文关键词: P16 Cyclin D1 Survivin |
基金项目: |
|
Hits: 791 |
Download times: 1217 |
中文摘要: |
目的:探讨抑癌基因p16、细胞周期蛋白cyclin D1 和凋亡抑制基因survivin 在膀胱移行细胞癌中的表达及意义。方法:膀胱
移行细胞癌组67 例,10 例正常正常膀胱粘膜作为对照,采用免疫组织化学方法检测p16 和cyclin D1、survivin 蛋白表达,然后分
析上述三种蛋白在膀胱癌组织中的表达情况,以及随着不同临床分期和病理分级表达的变化。结果:所有膀胱癌患者平均年龄
58.16 岁,其中男性患者38 例。免疫组织化学分析表明,p16 和cyclin D1、survivin 蛋白均表达在细胞的细胞核。膀胱癌组织中P16
表达明显低于正常对照组,而cyclin D1 和survivin 表达明显高于正常对照组。随着临床分期的进展,p16 表达明显下降,cyclinD1
表达明显上升;而随着膀胱癌病理分级升高,p16 表达明显下降,survivin 表达上升。此外,膀胱癌组织中,p16 与cyclin D1p16 之间
存在着明确的负相关。结论:p16、cyclin D1、survivin 在膀胱移行细胞癌的生物学行为中起重要作用,p16,cyclin D1 和survivin 与
膀胱移行细胞癌的恶性进展有关。 |
英文摘要: |
Objective: To investigate the expression of p16, cyclin D1 or survivin as well as the clinical significance in transitional
cell carcinoma of bladder. Methods: 67 specimens were derived by surgical operation. p16 protein, cyclin D1 and survivin were
investigated by immunohistochemical method. Results: 67 patients with transitional cell carcinoma of bladder were enrolled in the study,
with mean age of 58.16 years. 38 cases were men. The expression of p16 was significant lower than the normal controls, and the
expression of cyclin D1 and survivin were much higher than the normal controls. With the clinical stage progressed, the p16 expression
level down-regulated, and cyclin D1 up-regulated; while with the tumor grade increased, the p16 expression down-regulated, and the
survivin expression up-regulated. Moreover, the expression of p16 was negatively correlated to the expression of cyclin D1. Conclusions:
p16, cyclin D1 and survivin play an important role in the behavior of biochemical in TCC. The expression of p16, cyclin D1 and survivin
all involved in the progress of transitional cell carcinoma of bladder. |
View Full Text
View/Add Comment Download reader |
Close |
|
|
|